Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Impact of Tenofovir Disoproxil Fumarate in Healthy Males
NCT00648817Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tenofovir disoproxil fumarate in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Insulin-mediated glucose disposal at 2 weeks. Started Jul 2006; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00648817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00648817.